A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery following autologous stem cell transplantation
Sign Up to like & getrecommendations! Published in 2017 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-017-3923-1
Abstract: Filgrastim-sndz (Zarxio®) was approved by the FDA in March 2015 as a biosimilar product of its reference product, filgrastim (Neupogen®) for all five indications. The NCCN Clinical Practice Guidelines has incorporated filgrastim-sndz into its recommendations… read more here.
Keywords: chemotherapy; filgrastim filgrastim; filgrastim; safety ... See more keywords
Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated “same-day” ( 72 h): findings from the MONITOR-GCSF study
Sign Up to like & getrecommendations! Published in 2018 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-018-4513-6
Abstract: PurposeGranulocyte colony-stimulating factors (G-CSFs) are indicated for prophylaxis or management of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN). Guidelines recommend G-CSF 24–72 h following chemotherapy; however, some evidence suggests that G-CSF initiated read more here.
Keywords: chemotherapy; filgrastim; per guidelines; day per ... See more keywords
Filgrastim loading in PLGA and SLN nanoparticulate system: a bioinformatics approach
Sign Up to like & getrecommendations! Published in 2020 at "Drug Development and Industrial Pharmacy"
DOI: 10.1080/03639045.2020.1788071
Abstract: Abstract Objective In this research work, we hypothesized to predict the nanoparticulate system, best suited for targeted delivery of filgrastim. Significance: Targeted delivery of filgrastim to bone marrow is required to decrease the incidence of… read more here.
Keywords: filgrastim; system; sln; nanoparticulate system ... See more keywords
Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: Simulation study.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of medical economics"
DOI: 10.1080/13696998.2023.2183680
Abstract: AIMS This study estimated, for Saudi Arabia, the cost-efficiency of converting patients from reference Neupogen1 and Neulastim to one of two filgrastim biosimilars (Nivestim, Zarzio); the budget-neutral expanded access to supportive care with biosimilar filgrastim… read more here.
Keywords: cancer; filgrastim; conversion; care ... See more keywords
Filgrastim induced thrombocytopenia
Sign Up to like & getrecommendations! Published in 2020 at "BMJ Case Reports"
DOI: 10.1136/bcr-2020-234584
Abstract: Drug-induced thrombocytopenia (DITP) is suggested by severe thrombocytopenia with subsequent recovery of platelet count after removal of the offending drug. The diagnosis is ascertained when there is reproducibility of thrombocytopenia with repeated exposure. Filgrastim is… read more here.
Keywords: induced thrombocytopenia; stem cell; filgrastim; filgrastim induced ... See more keywords
Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-130914
Abstract: Background: Autologous stem cell transplantation (ASCT) performed early in the disease course or at first relapse leads to improved progression-free and overall survival in transplant-eligible patients with multiple myeloma (MM). Filgrastim, a recombinant granulocyte colony-stimulating… read more here.
Keywords: administration; filgrastim; group; stem cell ... See more keywords
Immunogenicity Assessment of Tbo-Filgrastim in Cancer Patients Receiving Chemotherapy
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.2274.2274
Abstract: Introduction: Neutropenia is the primary cause of chemotherapy (CT) delays, interruptions, and dose reductions, potentially compromising patient outcomes, including survival and complete response rates. Granulocyte colony-stimulating factors (G-CSFs), which support the proliferation, differentiation, and activation… read more here.
Keywords: sample; filgrastim; immunogenicity; tbo filgrastim ... See more keywords
Analytical Comparison of the Originator Granulocyte-colony Stimulating Factor Filgrastim and its Biosimilars.
Sign Up to like & getrecommendations! Published in 2018 at "Current pharmaceutical design"
DOI: 10.2174/1381612824666181109163118
Abstract: PURPOSE Filgrastim, a recombinant human granulocyte colony-stimulating factor (rhG-CSF) produced in Escherichia coli, is indicated for treatment of neutropenia-related conditions in cancer patients. It has been marketed as Neupogen since 1991. In 2006, biosimilar rhG-CSF… read more here.
Keywords: stimulating factor; colony stimulating; filgrastim; granulocyte colony ... See more keywords